CD274 and non-small cell lung carcinoma: Emerging peripheral blood-based biomarkers such as soluble PD-L1 in exosomes have shown promise as prognostic and predictive markers in checkpoint inhibitor-treated NSCLC patients, supporting the role of liquid biopsy approaches [32,33].